Medtech Insight is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

People Power: How The Crowd May Shape The Funding And Development Of Drugs

Executive Summary

Companies are sprouting across the pharma value chain that harness the voices of patients and other individual stakeholders to drive the research, development, and financing of drugs. Pharma is taking tentative steps toward using these methods, but high barriers remain to their systematic integration in R&D.

Advertisement

Related Content

FDA Acquires Trove Of Rx Safety Data Through Alliance With PatientsLikeMe
Deals Of The Week Looks At The Intersection Of Patient Empowerment, Generic Drugs And Macaroni & Cheese
Financings Of The Fortnight Looks To The High-Tech Sector For New Life-Science Capital Sources
Facebook As A CRO: Social Networks Become Factor In Clinical Trial Designs
Investing A La Carte: Making Separate Bets on Discovery and Development to Boost Near-Term Returns
PatientsLikeMe.com Social Web Site Is Resource For Drug Market Research

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

IV003987

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel